Application Detail

Description of Medical Service

Dinutuximab beta is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response. Dinutuximab beta is an antibody directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. After binding, dinutuximab beta induces cell death through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Description of Medical Condition

Neuroblastoma is an embryonal tumour of the autonomic nervous system and usually occurs in young children. The tumours are found in sympathetic nervous system tissues, typically in the adrenal medulla or paraspinal ganglia and can present as mass lesions in the neck, chest, abdomen, or pelvis.

Reason for Application

Health technology assessent

Medical Service Type

Therapeutic

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

-

Consultation Survey

Consultation Survey (PDF 561 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation

-

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 741 KB)
Public Summary Document (Word 596 KB)

Meetings for this Application

PASC

-

ESC

12 June 2020

MSAC

28-29 July 2020